Compugen Ltd. Form 20-F Summary (Fiscal Year Ended Dec 31, 2003)
Business Context and Reporting Period
Company: Compugen Ltd.
Reporting Period: Fiscal year ended December 31, 2003.
Business Model: A genomics-based drug and diagnostic discovery company. Compugen utilizes computational biology (LEADS platform) to identify therapeutic proteins and diagnostic markers. The company is shifting focus from selling software tools (e.g., Bioccelerator, which was divested in 2003) to internal discovery and licensing of product candidates.
Headquarters: Tel Aviv, Israel, with U.S. operations in New Jersey, Maryland, and California.
Key Financial Metrics
| Metric (in thousands USD) | 2003 | 2002 |
|---|---|---|
| Total Revenues | $8,826 | $11,097 |
| Net Loss | $(11,442) | $(12,204) |
| Operating Loss | $(14,216) | $(15,044) |
| Research & Development Expenses | $13,306 | $14,170 |
| Cash & Cash Equivalents | $7,910 | $5,289 |
| Short-term Marketable Securities | $8,797 | $12,918 |
| Long-term Marketable Securities | $43,803 | $18,940 |
| Total Liquid Assets | ~$60.5 million | ~$37.1 million |
| Accumulated Deficit | $(92,034) | $(80,592) |
Liquidity: As of December 31, 2003, the company held approximately $60.5 million in cash, cash equivalents, and marketable securities. Management projects these funds are sufficient to support operations for at least the next two years.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 20% to $8.8 million. This was driven by a strategic shift away from commercializing computational products (Bioccelerator, LEADS, Genecarta) toward internal drug discovery. Product and service revenues dropped 27% year-over-year.
- Divestiture: The company sold its Bioccelerator product line in 2003, recognizing a capital gain of approximately $459,000.
- Deconsolidation: Effective July 1, 2003, the company deconsolidated its majority-owned subsidiary, Evogene Ltd. (agricultural biotechnology), following the adoption of FIN 46. Compugen is no longer the primary beneficiary of Evogene.
- Expense Management: Sales and marketing expenses decreased 31% due to reduced promotion of legacy software tools. R&D expenses decreased 6%, largely due to the devaluation of the Israeli Shekel against the U.S. Dollar and lower stock-based compensation.
- Customer Concentration: In 2003, Novartis Pharma A.G. and Abbott Laboratories each accounted for over 10% of product and service revenues, totaling approximately 52%.
Outlook, Risks, and Management Commentary
- Profitability: The company has a history of losses and expects to continue incurring net losses and negative cash flows in the future due to high R&D expenses. There is no assurance that profitability will ever be achieved.
- Strategic Focus: Future revenue is expected to derive primarily from the commercialization of therapeutic proteins and diagnostic markers discovered internally, rather than software licensing. The goal is to have a minimum of two therapeutic proteins enter human clinical trials annually in the mid-term.
- Capital Needs: While current liquidity is sufficient for two years, the company may need to raise additional capital in the future to fund discovery activities or acquisitions. Failure to raise capital could force a curtailment of operations.
- Key Risks:
- Discovery Risk: The company's novel approach to drug discovery may prove ineffective, or discovered candidates may lack commercial value.
- Collaboration Dependence: Commercialization relies on third-party partners who may not pursue development or may develop competing products.
- Intellectual Property: Risks include inability to obtain patents, third-party infringement claims, and the potential obsolescence of technologies due to public genomic data availability.
- Geopolitical: Operations are based in Israel; regional instability or military conflict could disrupt operations or affect the ability to raise capital.
- PFIC Status: There is a risk of classification as a Passive Foreign Investment Company (PFIC) for U.S. tax purposes, which could adversely affect U.S. shareholders.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $60.5 million cash position against the projected burn rate for the next 24 months.
- Revenue Transition: Assess the timeline and probability of generating revenue from new therapeutic/diagnostic licenses to replace declining software sales.
- Customer Concentration: Monitor the stability of relationships with Novartis and Abbott, which represent over half of product/service revenue.
- Evogene Status: Review the financial impact of the deconsolidation of Evogene and the terms of the convertible loan provided to Evogene by third-party lenders.
- Government Grants: Confirm continued eligibility for Israeli government R&D grants and "Approved Enterprise" tax benefits, which are material to the financial structure.
- Patent Portfolio: Evaluate the status of pending patent applications for discovered splice variants (e.g., PSA-LM, K-LM, VEGF114) and potential litigation risks.